Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,318 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Disease Clear all
Recruiting Phase 1 Interventional

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697
View directory record Official record
Conditions
Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions
cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed No phase listed Observational

Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System

NCT03614910
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Nanoknife Irreversible Electroporation
Device
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 7, 2026, 9:47 PM EDT
Not yet recruiting No phase listed Observational

Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients

NCT07591480
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Interviews
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Not listed No phase listed Observational

Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study

NCT03951324
View directory record Official record
Conditions
Biliary Stricture, Pancreas Cancer, Cholangiocarcinoma, Bile Duct Cancer, Bile Duct Neoplasms Malignant, Bile Duct Neoplasms, Bile Duct Lesions, Bile Duct Obstruction, Bile Duct Diseases, Bile Duct Obstruction, Extrahepatic, Bile Duct Stenosi, Bile Duct Adenoma, Pancreatic Duct Stricture, Pancreatic Duct Stenosis, Pancreatic Duct Obstruction, Pancreatic Ductal Adenocarcinoma, Primary Sclerosing Cholangitis
Interventions
Interobserver agreement or Interrater agreement
Other
Lead sponsor
Innovative Digestive Health Education and Research Inc
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 7, 2026, 9:47 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05642962
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Carcinoma, Pancreatic Carcinoma Metastatic, Pancreatic Carcinoma Non-resectable, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
Pertzye
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 1 Interventional

Epidural Analgesia Use in Pancreatic Resections

NCT02681796
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer, Pancreas Neoplasms, Pancreatic Cancer
Interventions
Bupivacaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Not applicable Interventional

Preventing Depression and Anxiety: A Cystic Fibrosis-Specific Cognitive Behavioral Therapy Intervention

NCT03992027
View directory record Official record
Conditions
Depression, Anxiety
Interventions
CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis, Waitlist Control
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Palo Alto, California • Kansas City, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 7, 2026, 9:47 PM EDT
Recruiting Phase 2 Interventional

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Interventions
APL-101 Oral Capsules
Drug
Lead sponsor
Apollomics Inc.
Industry
Eligibility
18 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 7, 2026, 9:47 PM EDT
Not listed Phase 3 Interventional

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

NCT00005869
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Phase 2 Interventional Results available

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

NCT04059094
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BI 1265162, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Not applicable Interventional

Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer

NCT01760694
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Multi-Modality; IORT, Surgery, Radiation, Chemotherapy
Other
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 7, 2026, 9:47 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

High Resolution Micro OCT Imaging

NCT03256773
View directory record Official record
Conditions
Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 2 Interventional

Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

NCT00761241
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy, Pancreaticoduodenectomy
Drug · Biological · Radiation + 1 more
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 2 Interventional

Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer

NCT00003769
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
perillyl alcohol, surgical procedure
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 7, 2026, 9:47 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320
View directory record Official record
Conditions
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
432
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Not applicable Interventional

Clinical Trial to Evaluate the Endoscopic Ultrasound Guided Celiac Plexus Block for Treatment of Pain in Chronic Pancreatitis

NCT03070210
View directory record Official record
Conditions
Pancreatitis, Chronic, Abdominal Pain
Interventions
EUS-celiac ganglia block (EUS-CGB), EUS-celiac plexus block (EUS-CPB)
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 7, 2026, 9:47 PM EDT
Completed No phase listed Observational

Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer

NCT00805688
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Questionnaires, Blood Draws, Pedometer
Behavioral · Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 1 Interventional

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

NCT04132505
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Binimetinib, Hydroxychloroquine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 1 Interventional

Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

NCT00003427
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Not applicable Interventional

Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations

NCT01387659
View directory record Official record
Conditions
Diabetes, Immunosuppression
Interventions
Gastric emptying test
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 7, 2026, 9:47 PM EDT
Active, not recruiting Phase 2 Interventional

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

NCT02451982
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX pancreatic cancer, Nivolumab, Urelumab, BMS-986253
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Phase 1 Interventional

Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer

NCT00732082
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Gemcitabine, LAG-3
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Results available

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

NCT01519661
View directory record Official record
Conditions
Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
TBM100
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Little Rock, Arkansas • Denver, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

NCT02191761
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Hepatic Cancer, Pancreatic Cancer
Interventions
SM04755
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 9:47 PM EDT